We believe that the promising clinical data presented today SAR3419 further validate our TAP technology and the depth potential of our pipeline, said Daniel Junius, President and CEO. SAR3419 has demonstrated impressive efficacy and tolerability in heavily pretreated patients enrolled in this study, half of whom were refractory to rituximab. Sanofi plans to develop aggressively SAR3419, from advances in phase II trial by the end years.- SAR3419 is well tolerated. Of particular note is the lack of significant myelosuppression associated SAR3419 treatment, which is attractive for use in combination with standard chemotherapeutic agents.
- 33 percent of patients treated with SAR3419 at its MTD had an objective response .
Dr. Jennifer Neonatalogist Kloesz Children’s Hospital of Pittsburgh, said that although the majority of deliveries between 34 and 36 weeks are performed for medical reasons, there may be deliveries that can not be extended further. T We are always aggressively looking to stop working at 34 or 35 weeks and it may be that we need to start watching it.
B-cell lymphomas represent about 85 percent of non-Hodgkin’s lymphoma in the United States and represent about 4 percent of all. In 2010, over 65,000 people will be diagnosed with NHL and 20,000 people will die. The 5-year survival rate for this disease is about 67 percent 0.1
Additional data from this study will be presented at the International Conference on malignant lymphoma meeting in Lugano, Switzerland later this month.
It ‘was found that further improvements in the tolerability of SAR3419 could be achieved by switching to a regimen twice a week after the steady-state pharmacokinetics was achieved, because some toxic effects occurred only after 6 to 8 cycles of treatment . Following the amendment of the Protocol, SAR3419 is now under evaluation administered weekly for 4 weeks followed by one dose every two weeks for 4 additional doses.
SAR3419 was developed by ImmunoGen and licensed to Sanofi as part of a wider partnership. It consists of an antibody targeting CD19 developed by ImmunoGen with DM4 cell-killing agent linked company with one of ImmunoGen is designed linker.
- Among patients who received a dose of SAR3419 for which data were available for histology, tumor shrinkage of more than 20 percent was reported in:
- Drug Information. Fluoxetine Uses.
- Pain Relief Information.Generic Imitrex (Sumatriptan) . Drug Interactions
- The duration of response ranged from five weeks for at least 55 weeks, with three patients continued to face both cutting data for presentation.